{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:07:47Z","timestamp":1789193267720,"version":"build-2803163510"},"reference-count":24,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Radboud Oncology Fund","award":["ROF2413"],"award-info":[{"award-number":["ROF2413"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The diagnostic and therapeutic landscape for high-risk localised prostate cancer and synchronous metastatic hormone-sensitive prostate cancer (mHSPC) is rapidly evolving, driven by advances in imaging, risk stratification and systemic therapies, including the advent of precision medicine. High-quality real-world data integrating clinical, imaging, molecular, quality-of-life information and outcome data remain scarce. The PROspective Prostate Cancer Infrastructure (ProPCI) is a nationwide, multicentre observational cohort designed to collect comprehensive longitudinal data and biomaterials to support real-world evidence generation, facilitate biomarker discovery and enable future cohort multiple randomised controlled trials (cmRCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>ProPCI includes adult men with high-risk localised prostate cancer or synchronous mHSPC across hospitals in the Netherlands. Clinical data are extracted from electronic health records using a standardised protocol and linked to national registries and healthcare use datasets. Patient-reported outcome measures are collected at baseline and regular intervals using validated instruments. Serial blood samples are biobanked for circulating tumour DNA and other molecular analyses. Outcomes include diagnostic and treatment patterns, Prostate-specific antigen kinetics, time to castration-resistant prostate cancer, radiological and clinical progression, health-related quality of life trajectories and healthcare use, including expenditure and exploratory biomarker associations. Statistical methods include descriptive analyses, time-to-event models, mixed-effects models and biomarker-outcome correlates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been obtained from the Committee on Research Involving Human Subjects (CMO) of Radboudumc. Written informed consent will be obtained from every participating patient and covers: (1) extraction and linkage of clinical, imaging, pathology and registry data, (2) future contact for potential cmRCT participation; and optional components (3) quality-of-life questionnaires, (4) collection of additional blood samples and (5) use of biomaterials for genomic testing. Results will be disseminated through peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07560748\">NCT07560748<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-121662","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:15:50Z","timestamp":1789190150000},"page":"e121662","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["PROspective Prostate Cancer Infrastructure: study protocol for the ProPCI \u2018trials within cohorts\u2019 study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07560748","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-008X","authenticated-orcid":false,"given":"Ruben O.","family":"Wissing","sequence":"first","affiliation":[{"name":"Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands"},{"name":"Department of Medical Oncology, Radboudumc, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-6130","authenticated-orcid":false,"given":"Tessa","family":"van Elst","sequence":"additional","affiliation":[{"name":"Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands"},{"name":"Department of Medical Oncology, Radboudumc, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Sedelaar","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboudumc, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jan","family":"Smeenk","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Radboudumc, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tergooi MC, Hilversum, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"van Dodewaard-de Jong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Meander MC, Amersfoort, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne P.","family":"Lont","sequence":"additional","affiliation":[{"name":"Department of Urology, Meander MC, Amersfoort, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-5393","authenticated-orcid":false,"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Noordwest Ziekenhuisgroep, Alkmaar, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Luijendijk-de Bruin","sequence":"additional","affiliation":[{"name":"Department of Urology, Martini Hospital, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addy C.M.","family":"van de Luijtgaarden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc A.J.","family":"Roelofs","sequence":"additional","affiliation":[{"name":"Department of Urology, Treant Care Group Hospital Location Scheper, Emmen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[{"name":"Department of Urology, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"Department of Urology, Catharina Hospital, Eindhoven, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiko J.","family":"Bloemendal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboudumc, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul A.","family":"van Basten","sequence":"additional","affiliation":[{"name":"Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboudumc, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091122153333000_16.9.e121662.1","unstructured":"IKNL . Cijfers over prostaatkanker. 2025. Available: https:\/\/iknl.nl\/Kankersoorten\/Prostaatkanker\/Cijfers [Accessed 6 Oct 2025]."},{"key":"2026091122153333000_16.9.e121662.2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026091122153333000_16.9.e121662.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-96065-9","article-title":"The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer","volume":"15","author":"van Elst","year":"2025","journal-title":"Sci Rep"},{"key":"2026091122153333000_16.9.e121662.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.831429","article-title":"PSMA PET in Imaging Prostate Cancer","volume":"12","author":"Tsechelidis","year":"2022","journal-title":"Front Oncol"},{"key":"2026091122153333000_16.9.e121662.5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euros.2025.03.007","article-title":"How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View","volume":"75","author":"Oprea-Lager","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"2026091122153333000_16.9.e121662.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2026091122153333000_16.9.e121662.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"2026091122153333000_16.9.e121662.8","doi-asserted-by":"crossref","unstructured":"van Elst T , Lopez P , Buffart LM , et al . Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis. Eur Urol Focus 2025;11. doi:10.1016\/j.euf.2025.12.001","DOI":"10.1016\/j.euf.2025.12.001"},{"key":"2026091122153333000_16.9.e121662.9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2021.10.005","article-title":"Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review","volume":"4","author":"Van der Eecken","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026091122153333000_16.9.e121662.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072572","article-title":"TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment","volume":"13","author":"van Elst","year":"2023","journal-title":"BMJ Open"},{"key":"2026091122153333000_16.9.e121662.11","doi-asserted-by":"crossref","unstructured":"Relton C , Torgerson D , O\u2019Cathain A , et al . Rethinking pragmatic randomised controlled trials: introducing the \u201ccohort multiple randomised controlled trial\u201d design. BMJ 2010;340. doi:10.1136\/bmj.c1066","DOI":"10.1136\/bmj.c1066"},{"key":"2026091122153333000_16.9.e121662.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.969"},{"key":"2026091122153333000_16.9.e121662.13","unstructured":"IQVIA . Patient finder solution. Amsterdam, Netherlands: IQVIA, Available: https:\/\/www.iqvia.com\/locations\/emea\/iqvia-connected-healthcare-platform\/iqvia-patient-finder-solution"},{"key":"2026091122153333000_16.9.e121662.14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2026091122153333000_16.9.e121662.15","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2026091122153333000_16.9.e121662.16","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"2026091122153333000_16.9.e121662.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N"},{"key":"2026091122153333000_16.9.e121662.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.07.030"},{"key":"2026091122153333000_16.9.e121662.19","unstructured":"Aben KK . Publiekssamenvatting prozib. 2020. Available: https:\/\/iknl.nl\/getmedia\/4056a764-332f-4eed-929e-6e34d320b2c0\/Publiekssamenvatting-ProZIB-feb-2020.pdf"},{"key":"2026091122153333000_16.9.e121662.20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5334\/ojb.36","article-title":"The Radboud Biobank: A Central Facility for Disease-Based Biobanks to Optimise Use and Distribution of Biomaterial for Scientific Research in the Radboud University Medical Center, Nijmegen","volume":"5","author":"Manders","year":"2018","journal-title":"Open J Bioresour"},{"key":"2026091122153333000_16.9.e121662.21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/0284186X.2016.1189094","article-title":"Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational","volume":"55","author":"Burbach","year":"2016","journal-title":"Acta Oncol (Madr)"},{"key":"2026091122153333000_16.9.e121662.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4242-4"},{"key":"2026091122153333000_16.9.e121662.23","unstructured":"IKNL . PRO-rcc: prospective cohort - renal cell carcinoma. 2020. Available: https:\/\/iknl.nl\/projecten\/pro-rcc"},{"key":"2026091122153333000_16.9.e121662.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047256","article-title":"Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the \u201ctrials within cohorts\u201d study ProBCI","volume":"11","author":"Richters","year":"2021","journal-title":"BMJ Open"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-121662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:15:54Z","timestamp":1789190154000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-121662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-121662"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-121662","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}